Health Care • Biotechnology: Pharmaceutical Preparations
$9.73 ▼ -0.03
(-0.31%)
MKT CAP: $643.9M • VOL: 3.20M
52W L $8 52W H $31
ROARABLE / RQD
D • 45/100
PIOTROSKI
2 / 9
BCAX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$155.6M | -$82.4M | -$39.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$137.9M | -$68.0M | -$52.0M |
| EBITDA (Normalized) | -$155.4M | -$82.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$106.8M | -$74.8M | -$45.6M |
| Capital Expenditures (CapEx) | $280.0K | $71.0K | — |
| Free Cash Flow (FCF) | -$107.1M | -$74.8M | -$45.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -40.3% | -45.0% | — |
| Cash & Short-Term Equivalents | $96.7M | $489.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $401.5M | $491.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BCAX.